Thalassemia — the world's most common single-gene disorder, where the full globin genotype determines whether someone is an asymptomatic carrier, has a treatable chronic condition, or has a transfusion-dependent disease.
Whole genome sequencing reads the complete alpha-globin (HBA1/HBA2) and beta-globin (HBB) gene clusters, resolving every deletion, point mutation, and compound heterozygous combination — the full architecture that standard carrier screens do not characterize.
Thalassemia
Thalassemia syndromes are autosomal recessive hemoglobinopathies caused by reduced or absent production of alpha- or beta-globin chains, leading to imbalanced globin chain synthesis, ineffective erythropoiesis, and chronic hemolytic anemia. Collectively, thalassemias are the most common single-gene disorders worldwide — an estimated 270 million people carry a thalassemia variant, and approximately 60,000 severely affected children are born annually. Thalassemia carrier frequencies are highest in malaria-endemic regions: the Mediterranean, sub-Saharan Africa, the Middle East, South and Southeast Asia, and southern China.
Alpha-thalassemia is caused by deletions or mutations affecting the HBA1 and HBA2 genes on chromosome 16p13.3. Because there are four alpha-globin gene copies (two HBA1 and two HBA2 on each chromosome 16), alpha-thalassemia severity follows a dosage-dependent gradient: one gene deleted (alpha-thalassemia silent carrier), two genes deleted (alpha-thalassemia trait), three genes deleted (HbH disease, moderate anemia), four genes deleted (Hb Bart's hydrops fetalis, uniformly fatal in utero without intervention). Beta-thalassemia is caused by point mutations or small insertions/deletions in the HBB gene. Beta-thalassemia major (Cooley's anemia, beta⁰/beta⁰) requires lifelong transfusion; beta-thalassemia intermedia has variable severity; beta-thalassemia trait is asymptomatic.
The genetic architecture of thalassemia is among the most complex of any Mendelian disorder. Over 300 beta-globin variants and dozens of alpha-globin deletion types have been characterized. Compound heterozygosity — inheriting different thalassemia variants from each parent — creates phenotypes not predictable from either variant alone. Co-inheritance of alpha- and beta-thalassemia modifies disease severity: concurrent alpha-thalassemia reduces globin chain imbalance in beta-thalassemia, paradoxically ameliorating the condition. Gene therapy (betibeglogene autotemcel, approved 2022) and gene editing (exagamglogene autotemcel/exa-cel, approved 2023) offer curative potential for transfusion-dependent patients, making definitive genotyping directly treatment-enabling.
Alpha- and beta-thalassemia involve different genes and inheritance patterns. Compound heterozygous combinations create distinct clinical phenotypes not predictable from individual variant testing alone.
Standard carrier screening tests for common regional thalassemia variants. It cannot resolve the full alpha-globin deletion genotype, compound heterozygous states, or modifier loci that determine clinical severity and reproductive risk.
Alpha-globin gene copy number requires genome-level resolution — SNP panels cannot determine it
Alpha-thalassemia is predominantly caused by large deletions that remove one or both alpha-globin genes from a chromosome. Determining the number of residual functional alpha-globin gene copies — the primary determinant of clinical severity — requires deletion mapping with breakpoint characterization. SNP-based carrier screening panels do not detect gene deletions. Even targeted deletion testing (MLPA, Gap-PCR) evaluates only the most common regional deletion types and may miss rare or atypical deletions. Whole genome sequencing maps all alpha-globin deletions, determines precise gene copy number, and characterizes breakpoints — the information required to distinguish alpha-thalassemia trait ('cis' vs 'trans' deletion configurations) and predict hydrops fetalis risk.
Gene therapy eligibility requires the definitive genotype — not a screening result
The approval of betibeglogene autotemcel (Zynteglo, 2022) and exa-cel (Casgevy, 2023) for transfusion-dependent beta-thalassemia has made definitive HBB genotyping directly treatment-enabling. Gene therapy eligibility criteria specify the beta-thalassemia genotype and, in some protocols, exclude certain variant types. For patients being evaluated for curative gene therapy or gene editing, the complete globin genotype — including identification of any co-inherited alpha-thalassemia that may affect the treatment response — must be established with certainty. Whole genome sequencing provides this definitive genotype in a single, comprehensive test.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Thalassemia and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
